Related Experiment Video

Updated: Jan 15, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Controlling Temozolomide Efficacy by Light-Dependent Inhibition of O6‑Methylguanine DNA Methyltransferase

Ivonne R Lopez-Miranda1, Josef I Sim1, Gabrielle Juneau2

  • 1Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, Ontario L5L 1C6, Canada.

ACS Medicinal Chemistry Letters
|January 14, 2026
PubMed

Insights

Researchers developed a light-activated inhibitor for the O6-Methylguanine DNA Methyltransferase (MGMT) enzyme. This photoactivatable approach enhances temozolomide (TMZ) cancer therapy efficacy specifically in targeted areas, minimizing side effects on healthy tissues.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • O6-Methylguanine DNA Methyltransferase (MGMT) confers resistance to alkylating agents like temozolomide (TMZ) in cancer.
  • MGMT inhibitors can enhance TMZ efficacy but cause severe side effects due to nonselective inhibition in healthy cells.

Purpose of the Study:

  • To develop a photoactivatable MGMT inhibitor for targeted cancer therapy.
  • To enhance temozolomide (TMZ) sensitivity in cancer cells using light-controlled inhibition.

Main Methods:

  • Development of a novel photoactivatable O6-Methylguanine DNA Methyltransferase (MGMT) inhibitor.
  • Testing the inhibitor's efficacy in T98G cells under irradiation.
  • Assessing the enhancement of temozolomide (TMZ) sensitivity post-irradiation.

Main Results:

  • The photoactivatable MGMT inhibitor effectively inhibited MGMT activity upon light irradiation.
  • Irradiation led to enhanced sensitivity to temozolomide (TMZ) in T98G cells.
  • Demonstrated a strategy for light-controlled, tissue-specific enhancement of TMZ efficacy.

Conclusions:

  • Photoactivatable MGMT inhibition offers a promising strategy for spatially controlled cancer therapy.
  • This approach allows for targeted enhancement of TMZ efficacy in cancerous regions while sparing healthy tissues.
  • Light-activated drug delivery minimizes systemic toxicity associated with conventional MGMT inhibitors.
Keywords:
O6-Methylguanine DNA MethyltransferasePhotocaged-PaTrin-2Temozolomide

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.4K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.0K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K